Measuring real-time PK/PD by monitoring aberrant chaperone activity

A Memorial Sloan Kettering Cancer Center team developed an imaging probe for aberrant protein networks that could guide more optimal drug dosing and scheduling earlier in development.

In cancer, tumor biopsy collection as well as heterogeneity within tumors and among patients present logistical and ethical barriers to drug time-concentration course calculations. PK/PD models are instead based on bulk plasma sampling and may not reflect intratumoral drug concentrations, which can lead to suboptimal drug dosing and scheduling and a higher rate of failure in the clinic. ...